# NCT03698019 (NCT03698019)

> A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03698019
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma
- Interventions: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Pembrolizumab; Therapeutic Conventional Surgery
- Enrollment: 313
- Primary outcome: Two-Year Event-Free Survival Rate

## Commentary we found

- X threads: 39
- YouTube: 33
- Podcasts: 33

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03698019

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03698019", "email": "<work email>"}; the inbox owner confirms by the emailed link.